Interleukin-34 as a Robust Predictor of No-Reflow Phenomenon in ST-Elevation Myocardial Infarction: Insights into Inflammatory Mechanisms and Clinical Implications

Basit Öğe Kaydı
dc.contributor.authorKarasu, Mehdi
dc.contributor.authorBolayir, Hasan Ata
dc.contributor.authorAktas, Ibrahim
dc.date.accessioned2026-06-19T06:38:14Z
dc.date.available2026-06-19T06:38:14Z
dc.date.issued2024
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjective: ST-elevation myocardial infarction (STEMI) poses a significant challenge despite advances in reperfusion strategies. The no-reflow phenomenon, characterized by inadequate microvascular blood flow restoration following successful revascularization, remains poorly understood. Inflammation, particularly interleukin-34 (IL-34), is implicated in cardiovascular disease, prompting investigation into its role in no-reflow. Methods: This observational study included 182 patients with STEMI (32 with no-reflow, 150 without) and 100 controls. Clinical and angiographic data were analyzed, and IL-34 levels were measured. Logistic regression and receiver operating characteristic (ROC) analysis assessed IL-34's predictive value for no-reflow. Results: Patients with no reflow exhibited elevated IL-34 levels compared with controls and those without no-reflow. Logistic regression identified IL-34 as an independent predictor of no-reflow (odds ratio: 1,020, p<0.001). ROC analysis showed IL-34's significant predictive value (area under the curve: 0.972, p<0.001). Conclusion: IL-34 emerges as a robust predictor of no-reflow in STEMI, potentially reflecting its role in macrophage activation and the inflammatory response. These findings suggest a novel avenue for understanding and mitigating no-reflow in STEMI, paving the way for targeted therapies. Early identification of high-risk patients could inform tailored interventions, ultimately improving STEMI outcomes. Further research is warranted to elucidate IL-34's mechanistic involvement and validate its predictive value in larger cohorts.
dc.identifier.doi10.12996/gmj.2024.4054
dc.identifier.endpage381
dc.identifier.issn2147-2092
dc.identifier.issue4
dc.identifier.orcid0000-0002-3557-1175
dc.identifier.orcid0000-0003-1713-3451
dc.identifier.scopus2-s2.0-85207840369
dc.identifier.scopusqualityN/A
dc.identifier.startpage376
dc.identifier.trdizinid1347504
dc.identifier.urihttps://doi.org/10.12996/gmj.2024.4054
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1347504
dc.identifier.urihttps://hdl.handle.net/20.500.12899/5451
dc.identifier.volume35
dc.identifier.wosWOS:001337072400006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofGazi Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260612
dc.subjectInterleukin-34
dc.subjectSt-Elevation Myocardial Infarction
dc.subjectNo- Reflow Phenomenon
dc.titleInterleukin-34 as a Robust Predictor of No-Reflow Phenomenon in ST-Elevation Myocardial Infarction: Insights into Inflammatory Mechanisms and Clinical Implications
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu